Compare iShares China Large-Cap ETF (FXI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Sana Biotechnology Inc — how do they compare? iShares China Large-Cap ETF trades at $34.6, while Sana Biotechnology Inc trades at $3.41 (market cap $987.94M). Which is the better fit depends on your goals.
| FXI | SANA | |
|---|---|---|
52-Week High | $41.75 | $5.92 |
52-Week Low | $31.59 | $2.68 |
Market Cap | — | $987.94M |
Sector | — | Health |
Enterprise Value | — | $962.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares China Large-Cap ETF (FXI) trades at $34.535, up 2.27% on the day, with technical indicators showing a bullish overall signal despite some overbought RSI readings. Recent news highlights China's significant push into AI and electric vehicles, including a reported $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, which could benefit the large-cap Chinese companies held within the fund.
The outlook for FXI is tied to China's economic policy execution and its success in strategic sectors like AI and EVs. Key opportunities include exposure to state-backed industrial and tech giants, while risks stem from U.S.-China tech rivalry, regulatory shifts, and the potential for Chinese equities to act as a value trap despite apparent undervaluation.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
